<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296801</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP FB-11</org_study_id>
    <secondary_id>WI180455</secondary_id>
    <nct_id>NCT02296801</nct_id>
  </id_info>
  <brief_title>A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer</brief_title>
  <acronym>PALLET</acronym>
  <official_title>A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at effects the combination of palbociclib and letrozole may have on&#xD;
      estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative&#xD;
      breast cancer tumors which have not yet been treated. Letrozole is a type of endocrine&#xD;
      therapy called an aromatase inhibitor (AI) and is standard treatment for post-menopausal&#xD;
      women with ER-positive/HER2-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FB-11 study is a Phase II, randomized, open label, four arm study to examine the&#xD;
      biological and clinical effect of neoadjuvant letrozole with or without palbociclib in the&#xD;
      first-line treatment of estrogen-receptor (ER) positive, HER2-negative early invasive breast&#xD;
      cancer. The co-primary aims of this study are to to compare the changes in the proliferation&#xD;
      marker Ki67, and to compare clinical response after 14 weeks of therapy with letrozole with&#xD;
      or without palbociclib.&#xD;
&#xD;
      The FB-11 study initiative is a joint partnership between the NSABP Foundation, Inc. (NSABP)&#xD;
      Department of Site and Study Management (DSSM) and United Kingdom (UK) co-investigators at&#xD;
      the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research (ICR). Parallel&#xD;
      protocols will be conducted in the US and Canada (FB-11), and the UK (PALLET) with joint&#xD;
      analysis of interim and final data.&#xD;
&#xD;
      Postmenopausal women, newly diagnosed with ER-positive/HER2-negative early breast cancer, who&#xD;
      are suitable candidates for neoadjuvant endocrine therapy will be invited to join the&#xD;
      FB-11/PALLET trial. Approximately 306 patients will be accrued to this study. Each&#xD;
      collaborative group will recruit at least 1/3 and no more than 2/3 of the target accrual.&#xD;
&#xD;
      Patients will be randomized to one of four treatment arms (3:2:2:2 ratio). Treatment in the&#xD;
      first 14 weeks of neoadjuvant therapy will be:Arm A Letrozole alone; Arm B Letrozole for 2&#xD;
      weeks followed by letrozole + palbociclib to week 14; Arm C Palbociclib for 2 weeks followed&#xD;
      by letrozole + palbociclib to week 14; Arm D Letrozole + palbociclib to week 14.&#xD;
&#xD;
      Letrozole will be administered orally as a 2.5mg daily tablet. Palbociclib will be&#xD;
      administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7&#xD;
      days) off of a 4 week [28 day] cycle.&#xD;
&#xD;
      The end of study therapy for patients in Arm A will be completion of week 14. Patients in&#xD;
      Arms B, C, and D will complete study therapy following 14 days of palbociclib in the final&#xD;
      treatment cycle past 14 weeks if treatment delays have occurred.&#xD;
&#xD;
      Note: After week 14 (end of study therapy) all patients should continue letrozole until&#xD;
      surgery. Letrozole is not considered study therapy beyond completion of week 14 for Arm A or&#xD;
      after 14 days of palbociclib in the final treatment cycle for patients in Arms B, C, and D.&#xD;
&#xD;
      Following completion of study therapy, surgery will be scheduled for 15-18 weeks&#xD;
      post-randomization. Post-surgical treatment will be at discretion of treating clinician,&#xD;
      following local protocols, and not influenced by allocation of treatment within the&#xD;
      FB-11/PALLET study.&#xD;
&#xD;
      Toxicity will be graded according to the National Cancer Institute (NCI) Common Terminology&#xD;
      Criteria for Adverse Events version 4.0 (CTCAE v4.0).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the proliferation marker Ki67 (% positive tumor cells)</measure>
    <time_frame>Baseline and at 14 weeks</time_frame>
    <description>The change in Ki67 from baseline to 14 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Complete Response (cCR): Number of patients who have resolution of measurable lesions or no new lesions or other signs of disease progression compared to baseline.</measure>
    <time_frame>Baseline and at 14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response (pCR): Number of patients with no lesions in breast and nodes at time of surgery</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative Endocrine Prognostic Index (PEPI) score:</measure>
    <time_frame>14 weeks</time_frame>
    <description>The PEPI score estimates the risk of cancer recurrence after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>baseline and weekly through 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular and genetic profiles of samples collected.</measure>
    <time_frame>Baseline, week 2 and week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Ki67 marker</measure>
    <time_frame>Week 2 and week 14</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Carcinoma</condition>
  <condition>Breast Tumors</condition>
  <arm_group>
    <arm_group_label>A: letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>letrozole 2.5 mg tablet orally daily for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: letrozole then letrozole + palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>letrozole 2.5 mg orally daily plus beginning 2 weeks after starting letrozole, palbociclib 125 mg capsule orally daily for 1 week then 1 week off, then a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of letrozole therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: palbociclib then letrozole + palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>palbociclib 125 mg capsule orally daily (for a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of palbociclib) plus beginning 2 weeks after starting palbociclib, letrozole 2.5 mg tablet orally daily for a total of 12 weeks from start of letrozole therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: letrozole + palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>letrozole 2.5 mg tablet orally daily for a total of 14 weeks plus palbociclib 125 mg capsule orally daily for a 3 weeks on and 1 week off cycle, for a total of 14 weeks from start of therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>A: letrozole</arm_group_label>
    <arm_group_label>B: letrozole then letrozole + palbociclib</arm_group_label>
    <arm_group_label>C: palbociclib then letrozole + palbociclib</arm_group_label>
    <arm_group_label>D: letrozole + palbociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palbociclib</intervention_name>
    <arm_group_label>B: letrozole then letrozole + palbociclib</arm_group_label>
    <arm_group_label>C: palbociclib then letrozole + palbociclib</arm_group_label>
    <arm_group_label>D: letrozole + palbociclib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be postmenopausal women defined as: Age 56 or older with no spontaneous&#xD;
             menses for at least 12 months prior to study entry; or Age 55 or younger with no&#xD;
             menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to&#xD;
             hysterectomy) and with a documented estradiol level in the postmenopausal range&#xD;
             according to local institutional/laboratory standard; or Age greater than or equal to&#xD;
             18 with documented bilateral oophorectomy.&#xD;
&#xD;
          -  Operable ER-positive/HER2- negative, invasive early breast cancer, suitable for&#xD;
             neoadjuvant AI treatment. HER2-negative as determined by American Society of Clinical&#xD;
             Oncology - College of American Pathologists (ASCO-CAP) guidelines.&#xD;
&#xD;
          -  No known severe hypersensitivity reactions to compounds similar to palbociclib or&#xD;
             palbociclib excipients or to endocrine treatments.&#xD;
&#xD;
          -  A breast tumor with an ultrasound size of at least 2.0 cm.&#xD;
&#xD;
          -  Patients must have the ability to swallow oral medication.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  At the time of randomization, blood counts performed within 4 weeks prior to&#xD;
             randomization must meet the following criteria: absolute neutrophil count (ANC) must&#xD;
             be greater than or equal to 1500/mm3; Platelet count must be greater than or equal to&#xD;
             100,000/mm3; Hemoglobin must be greater than or equal to 10 g/dL.&#xD;
&#xD;
          -  international normalized ratio (INR) must be within normal limits of the local&#xD;
             laboratory ranges.&#xD;
&#xD;
          -  The following criteria for evidence of adequate hepatic function performed within 4&#xD;
             weeks prior to study entry must be met: total bilirubin must be less than or equal to&#xD;
             upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation&#xD;
             greater than ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving&#xD;
             slow conjugation of bilirubin; and alkaline phosphatase must be must be less than or&#xD;
             equal to 1.5 x ULN for the lab; and aspartate aminotransferase (AST) and alanine&#xD;
             aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab.&#xD;
&#xD;
          -  Serum creatinine performed within 4 weeks prior to study entry must be less than or&#xD;
             equal to 1.25 x ULN or estimated creatinine clearance less than 60 mL/min (as&#xD;
             calculated using the method standard for the institutions).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C with abnormal liver function tests.&#xD;
&#xD;
          -  HIV positive patients receiving antivirals.&#xD;
&#xD;
          -  Premenopausal or peri-menopausal women.&#xD;
&#xD;
          -  Inflammatory/inoperable breast cancer.&#xD;
&#xD;
          -  HER2-positive as determined using ASCO-CAP Guidelines.&#xD;
&#xD;
          -  Concurrent use (defined as use within 4 weeks prior to baseline tissue sample being&#xD;
             taken) of hormone replacement therapy (HRT) or any other estrogen-containing&#xD;
             medication (including vaginal estrogens)&#xD;
&#xD;
          -  Prior endocrine therapy for breast cancer.&#xD;
&#xD;
          -  Any invasive malignancy within previous 5 years (other than basal cell carcinoma or&#xD;
             cervical carcinoma in situ).&#xD;
&#xD;
          -  Other nonmalignant systemic disease that would preclude the patient from receiving&#xD;
             study treatment or would prevent required follow up such as: Active infection or&#xD;
             chronic infection requiring chronic suppressive antibiotics; Malabsorption syndrome,&#xD;
             ulcerative colitis, inflammatory bowel disease, resection of the stomach or small&#xD;
             bowel, or other disease or condition significantly affecting gastrointestinal&#xD;
             function; Chronic daily treatment with corticosteroids with a dose of greater than or&#xD;
             equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids); Seizure&#xD;
             disorders requiring medication.&#xD;
&#xD;
          -  Diagnosis by fine needle aspiration (FNA) alone or excisional biopsy or lumpectomy&#xD;
             performed prior to study entry.&#xD;
&#xD;
          -  Surgical axillary staging procedure prior to study procedure (with exception of FNA or&#xD;
             core biopsy).&#xD;
&#xD;
          -  Definitive clinical or radiologic evidence of metastatic disease.&#xD;
&#xD;
          -  History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral&#xD;
             ductal carcinoma in situ (DCIS) treated with radiotherapy or contralateral invasive&#xD;
             breast cancer at any time.&#xD;
&#xD;
          -  Any treatment, including radiotherapy, chemotherapy, and/or targeted therapy,&#xD;
             administered for the currently diagnosed breast cancer prior to study entry.&#xD;
&#xD;
          -  Use of any medication or substances that are strong inhibitors or inducers of CYP3A&#xD;
             isoenzymes.&#xD;
&#xD;
          -  Class III or Class IV myocardial disease as described by the New York Heart&#xD;
             Association; a recent history (within 6 months) of myocardial infarction, or&#xD;
             symptomatic arrhythmia at the time of randomization. Class III: Patients with cardiac&#xD;
             disease resulting in marked limitation of physical activity. Such patients are&#xD;
             comfortable at rest. Less than ordinary physical activity that causes fatigue,&#xD;
             palpitation, dyspnea, or anginal pain. Class IV: Patients with cardiac disease&#xD;
             resulting in inability to perform any physical activity without discomfort. Symptoms&#xD;
             of cardiac insufficiency or anginal syndrome may be present even at rest.&#xD;
&#xD;
          -  QTc greater than 480 msec or a family or personal history of long or short QT&#xD;
             syndrome, Brugada syndrome or know history of QTc prolongation, or Torsade de Pointes&#xD;
             (TdP).&#xD;
&#xD;
          -  The investigator should assess the patient to determine if she has any psychiatric or&#xD;
             addictive disorder or other condition that, in the opinion of the investigator, would&#xD;
             preclude her from meeting the study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center-Todd Cancer Institute</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists of Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare Pavillion</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - Suburban, Norton Medical Plaza II</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - Brownsboro Medical Plaza I</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro-Minnesota CCOP</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Women's Cancer Centers</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Oncology and Hematology Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Ortenzio Cancer Center</name>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Martha Jefferson Hospital-Phillips Family Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W-1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Universite Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton Keynes Hospital</name>
      <address>
        <city>Milton Keynes</city>
        <state>Buckinghamshire</state>
        <zip>MK6 5LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hinchingbrooke Hospital</name>
      <address>
        <city>Huntingdon</city>
        <state>Cambridgeshire</state>
        <zip>PE29 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital, Treliske</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend Hospital</name>
      <address>
        <city>Westcliffe-on-sea</city>
        <state>Essex</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <state>Kent</state>
        <zip>DA2 8DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget University Hospital</name>
      <address>
        <city>Great Yarmouth</city>
        <state>Norfolk</state>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <state>Somerset</state>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston General Hospital</name>
      <address>
        <city>Weston-Super-Mare</city>
        <state>Somerset</state>
        <zip>BS23 4TQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salisbury Hospital</name>
      <address>
        <city>Salisbury</city>
        <state>Wiltshire</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidderminster Hospital</name>
      <address>
        <city>Kidderminster</city>
        <state>Worcestershire</state>
        <zip>DY11 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra Hospital</name>
      <address>
        <city>Redditch</city>
        <state>Worcestershire</state>
        <zip>B98 7UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Worcestershire</state>
        <zip>WR5 1DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital (Edinburgh Cancer Centre)</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James' University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnet Hospital</name>
      <address>
        <city>London</city>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whittington Hospital</name>
      <address>
        <city>London</city>
        <zip>N19 5NF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W8 6RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust, City Campus</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 9, 2021</submitted>
    <returned>August 2, 2021</returned>
    <submitted>October 4, 2021</submitted>
    <returned>November 2, 2021</returned>
    <submitted>November 3, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

